NYSEAMERICAN:CVMCEL-SCI Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.04 -0.67 (-5.27 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$12.00Now: $12.04▼$12.5950-Day Range$12.19MA: $13.96▼$16.7852-Week Range$6.00Now: $12.04▼$18.00Volume307,266 shsAverage Volume901,155 shsMarket Capitalization$453.11 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCEL-SCI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, CEL-SCI has a potential upside of 91.0% from its current price of $12.04.Amount of Analyst CoverageCEL-SCI has only been the subject of 1 research reports in the past 90 days. Previous Next 1.8 Community Rank Outperform VotesCEL-SCI has received 127 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCEL-SCI has received 225 “underperform” votes. (Add your “underperform” vote.)Community SentimentCEL-SCI has received 63.92% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote “Outperform” if you believe CVM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCEL-SCI does not currently pay a dividend.Dividend GrowthCEL-SCI does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CEL-SCI insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.06 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CVM Previous Symbol CUSIPN/A CIK725363 Webwww.cel-sci.com Phone+1-703-5069460Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares37,634,000Market Cap$453.11 million Next Earnings Date8/12/2020 (Estimated) OptionableOptionable $12.04 -0.67 (-5.27 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CVM News and Ratings via Email Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions How has CEL-SCI's stock been impacted by COVID-19 (Coronavirus)? CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CVM stock has increased by 23.6% and is now trading at $12.04. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CEL-SCI? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CEL-SCI. When is CEL-SCI's next earnings date? CEL-SCI is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for CEL-SCI. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.10 million. View CEL-SCI's earnings history. What price target have analysts set for CVM? 1 Wall Street analysts have issued 12-month price objectives for CEL-SCI's stock. Their forecasts range from $23.00 to $23.00. On average, they expect CEL-SCI's stock price to reach $23.00 in the next year. This suggests a possible upside of 91.0% from the stock's current price. View analysts' price targets for CEL-SCI. Has CEL-SCI been receiving favorable news coverage? News coverage about CVM stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CEL-SCI earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. View the latest news about CEL-SCI. Who are some of CEL-SCI's key competitors? Some companies that are related to CEL-SCI include Viela Bio (VIE), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), iShares Diversified Alternatives Trust (ALT), Altimmune (ALT), PureTech Health (PRTC), Trillium Therapeutics (TRIL), Oxford BioMedica (OXB), Nkarta (ANNX), Aptose Biosciences (APS), SIGA Technologies (SIGA) and Ibio (IBIO). View all competitors. What other stocks do shareholders of CEL-SCI own? Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Molecular Templates (MTEM), Savara (SVRA), TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA), Canopy Growth (CGC), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and TransEnterix (TRXC). Who are CEL-SCI's key executives? CEL-SCI's management team includes the following people: Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 60)Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 68)Dr. Eyal Talor, Chief Scientific Officer (Age 63)Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 78)Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 77) What is CEL-SCI's stock symbol? CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM." Who are CEL-SCI's major shareholders? CEL-SCI's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SG Americas Securities LLC (0.16%), Thoroughbred Financial Services LLC (0.06%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own CEL-SCI stock include Daniel H Zimmerman, Geert R Kersten, John Cipriano, Patricia B Prichep and Peter R Young. View institutional ownership trends for CEL-SCI. Which institutional investors are selling CEL-SCI stock? CVM stock was sold by a variety of institutional investors in the last quarter, including Thoroughbred Financial Services LLC. View insider buying and selling activity for CEL-SCI. Which institutional investors are buying CEL-SCI stock? CVM stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Patricia B Prichep, and Peter R Young. View insider buying and selling activity for CEL-SCI. How do I buy shares of CEL-SCI? Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CEL-SCI's stock price today? One share of CVM stock can currently be purchased for approximately $12.04. How big of a company is CEL-SCI? CEL-SCI has a market capitalization of $453.11 million. What is CEL-SCI's official website? The official website for CEL-SCI is www.cel-sci.com. How can I contact CEL-SCI? CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
